Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation

• Published in: American journal of hematology 2022-04, Vol.97 (4), p.401-410
• Main Authors: Abdallah, Nadine H., Habermann, Thomas, Buadi, Francis K., Gertz, Morie A., Lacy, Martha Q., Rajkumar, S. Vincent, Dingli, David, Go, Ronald S., Hayman, Suzanne R., Kumar, Shaji K., Kourelis, Taxiarchis, Warsame, Rahma, Kapoor, Prashant, Muchtar, Eli, Hwa, Yi L., Fonder, Amie L., Hobbs, Miriam A., Lin, Yi, Leung, Nelson, Binder, Moritz, Siddiqui, Mustaqeem A., Kyle, Robert A., Witzig, Thomas E., Dispenzieri, Angela
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Autografts; Castleman Disease - diagnosis; Castleman Disease - therapy; Castleman's disease; Chemotherapy; Cytotoxicity; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunoproliferative diseases; Interleukin 6; Lymphatic diseases; Lymphocytes; Patients; Retrospective Studies; Rituximab; Rituximab - therapeutic use; Stem Cell Transplantation; Transplantation, Autologous
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.26466

Castleman disease (CD) is a rare lymphoproliferative disease characterized by diverse clinical and pathologic features. Due to its rarity, there are limited studies comparing currently available therapies. The role of autologous stem cell transplantation (ASCT) in CD has not yet been established. In this paper, we describe the clinical characteristics, treatment choices, and outcomes in 34 Mayo Clinic patients diagnosed with multicentric CD from July 1, 2003 to April 30, 2018. Eighteen patients (53%) also met the criteria for POEMS, including 14 with the osteosclerotic variant. The first‐line treatments included: steroid monotherapy (4), cytotoxic chemotherapy (6), rituximab alone (8) or with chemotherapy (2), anti‐IL6 treatment (3), and ASCT (10). The median follow‐up was 4.8 (range: 0.1–15.2) years. The 5‐ and 10‐year overall survival rates were 84% and 71%, respectively. Sixteen patients received high‐dose chemotherapy followed by ASCT during their disease course. Among those, 14 had multicentric CD associated with POEMS. There were no transplant‐related deaths. All patients had at least a partial response to ASCT, most of whom achieved a complete response. The favorable outcomes seen with ASCT in this cohort suggest that transplantation may have a role in multicentric CD, particularly for patients with multicentric CD associated with POEMS.